In an interview to CNBC-TV18, Amey Chalke of HDFC Securities spoke about Q1 FY18 earnings from pharma sector.
We have buy rating on Glenmark Pharma. Operationally I don’t see any negatives at this point in time, he said.
His target price for Glenmark is above Rs 900.
He has also shared his views on Dr Reddy’s Laboratories (DRL) and Biocon.
For full interview, watch accompanying video...
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
